Platinum-based chemotherapy in metastatic triple-negative breast cancer: The Institut Curie experience

Annals of Oncology

Volumn 22, Issue 4, 2011, Pages 848-856

  Staudacher, L ^a   Cottu, P H ^a   Dieras V ^a   Vincent Salomon, A ^a   Guilhaume, M N ^a   Escalup, L ^a   Dorval, T ^a   Beuzeboc, P ^a   Mignot, L ^a   Pierga, J Y ^a,b  

^a INSTITUT CURIE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Ifosfamide; MBC; Platinum; Triple negative

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BEVACIZUMAB; BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MELPHALAN; NAVELBINE; PLATINUM DERIVATIVE; RECOMBINANT ERYTHROPOIETIN; TAXANE DERIVATIVE; THIOTEPA;

ADJUVANT THERAPY; ADULT; ANEMIA; APLASIA; AREA UNDER THE CURVE; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD TOXICITY; BREAST CANCER; CANCER MORTALITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FRANCE; HEARING DISORDER; HEARING LOSS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SEPSIS; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TINNITUS; TREATMENT DURATION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; VISCERAL METASTASIS; VOMITING;

EID: 79953313824     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq461     Document Type: Article

References (38)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533-543.
2. Bray F, McCarron P, Parkin DM. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 2004; 6: 229-239.
3. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009; 360: 790-800.
4. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
5. Bauer KR, Brown M, Cress RD et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007; 109: 1721-1728.
6. Schneider BP, Winer EP, Foulkes WD et al. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 2008; 14: 8010-8018.
7. Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology 2008; 52: 108-118.
8. Dent R, Hanna WM, Trudeau M et al. Pattern of metastatic spread in triplenegative breast cancer. Breast Cancer Res Treat 2009; 115: 423-428.
9. Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and longterm survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-1281.
10. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
11. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-5374.
12. van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
13. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol 2008; 26: 2568-2581.
14. Bergamaschi A, Kim YH, Wang P et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 2006; 45: 1033-1040.
15. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004; 4: 814-819.
16. Wilcken N, Dear R. Chemotherapy in metastatic breast cancer: a summary of all randomised trials reported 2000-2007. Eur J Cancer 2008; 44: 2218-2225.
17. Turner NC, Reis-Filho JS, Russell AM et al. BRCA1 dysfunction in sporadic basallike breast cancer. Oncogene 2007; 26: 2126-2132.
18. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
19. Rizzo JD, Lichtin AE, Woolf SH et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002; 20: 4083-4107.
20. Rakha EA, El-Sayed ME, Green AR et al. Prognostic markers in triple-negative breast cancer. Cancer 2007; 109: 25-32.
21. Kaplan HG, Malmgren JA. Impact of triple negative phenotype on breast cancer prognosis. Breast J 2008; 14: 456-463.
22. Rakha EA, El-Rehim DA, Paish C et al. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 2006; 42: 3149-3156.
23. Ratnam K, Low JA. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res 2007; 13: 1383-1388.
24. Heinemann V, Stemmler HJ, Wohlrab A et al. High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline- and taxane-pretreated metastatic breast cancer. Cancer Chemother Pharmacol 2006; 57: 640-646.
25. Tas F, Guney N, Derin D et al. Biweekly administration of gemcitabine and cisplatin chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer. Invest New Drugs 2008; 26: 363-368.
26. Nagourney RA, Link JS, Blitzer JB et al. Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. J Clin Oncol 2000; 18: 2245-2249.
27. Vassilomanolakis M, Koumakis G, Barbounis V et al. Vinorelbine and cisplatin in metastatic breast cancer patients previously treated with anthracyclines. Ann Oncol 2000; 11: 1155-1160.
28. Ray-Coquard I, Biron P, Bachelot T et al. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens. Cancer 1998; 82: 134-140.
29. Burch PA, Mailliard JA, Hillman DW et al. Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer: a North Central Cancer Treatment Group Trial. Am J Clin Oncol 2005; 28: 195-200.
30. Sirohi B, Arnedos M, Popat S et al. Platinum-based chemotherapy in triplenegative breast cancer. Ann Oncol 2008; 19: 1847-1852.
31. Bhattacharyya GS, Basu S, Agarwal V et al. Single institute phase II study of weekly cisplatinum and metronomic dosing of endoxan and methotrexate in second line metastatic breast cancer triple-negative. Eur J Cancer 2009 7 (3 Suppl): 18.
32. Byrski T, Gronwald J, Huzarski T et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010; 28: 375-379.
33. Byrski T, Huzarski T, Dent R et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 2009; 115: 359-363.
34. Silver DP, Richardson AL, Eklund AC et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 2010; 28: 1145-1153.
35. Leone BA, Vallejo CT, Romero AO et al. Ifosfamide and vinorelbine as first-line chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 2993-2999.
36. Kosmas C, Tsavaris NB, Malamos NA et al. Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer. J Clin Oncol 2001; 19: 119-126.
37. O'Shaughnessy J, Osborne C, Pippen J et al. Final results of a randomized phase II study demonstrating efficacy and safety of BSI-201, a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with gemcitabine/carboplatin (G/C) in metastatic triple negative breast cancer (TNBC). Cancer Res 2009; 69: abstract 3122.
38. Tutt A, Robson M, Garber JE et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376: 245-251.